Cogent Biosciences Valuation
| COGT Stock | USD 9.19 0.06 0.66% |
At this time, the firm appears to be undervalued. Cogent Biosciences shows a prevailing Real Value of $12.28 per share. The current price of the firm is $9.19. Our model approximates the value of Cogent Biosciences from analyzing the firm fundamentals such as Shares Owned By Insiders of 0.12 %, current valuation of 808.05 M, and Return On Equity of -0.78 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Cogent Biosciences' valuation include:
Price Book 4.9748 | Enterprise Value 808.1 M | Enterprise Value Ebitda (3.89) | Price Sales 1.3 K | Enterprise Value Revenue 925.407 |
Undervalued
Today
Please note that Cogent Biosciences' price fluctuation is somewhat reliable at this time. Calculation of the real value of Cogent Biosciences is based on 3 months time horizon. Increasing Cogent Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Cogent Biosciences' intrinsic value may or may not be the same as its current market price of 9.19, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.19 | Real 12.28 | Target 22.11 | Hype 9.2 | Naive 9.28 |
The intrinsic value of Cogent Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cogent Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cogent Biosciences helps investors to forecast how Cogent stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cogent Biosciences more accurately as focusing exclusively on Cogent Biosciences' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Cogent Biosciences' intrinsic value based on its ongoing forecasts of Cogent Biosciences' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Cogent Biosciences' closest peers.
Cogent Biosciences Cash |
|
Cogent Valuation Trend
Cogent Biosciences' real value is important for investors to make better decisions and a more accurate overall view of Cogent Biosciences' financial worth over time. Using both Cogent Biosciences' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Cogent Biosciences Total Value Analysis
Cogent Biosciences is currently forecasted to have valuation of 808.05 M with market capitalization of 1.02 B, debt of 18.85 M, and cash on hands of 325.56 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Cogent Biosciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
808.05 M | 1.02 B | 18.85 M | 325.56 M |
Cogent Biosciences Asset Utilization
One of the ways to look at asset utilization of Cogent is to check how much profit was generated for every dollar of assets it reports. Cogent Biosciences shows a negative utilization of assets of -0.44 percent, losing $0.004402 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Cogent Biosciences shows how discouraging it operates for each dollar spent on its assets.Cogent Biosciences Ownership Allocation
The majority of Cogent Biosciences outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Cogent Biosciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Cogent Biosciences. Please pay attention to any change in the institutional holdings of Cogent Biosciences as this could imply that something significant has changed or is about to change at the company.Cogent Biosciences Profitability Analysis
Net Loss for the year was (192.41 M) with loss before overhead, payroll, taxes, and interest of (121.63 M).About Cogent Biosciences Valuation
The stock valuation mechanism determines Cogent Biosciences' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Cogent Biosciences based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cogent Biosciences. We calculate exposure to Cogent Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cogent Biosciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -3.6 M | -3.4 M | |
| Pretax Profit Margin | (10.93) | (10.38) | |
| Operating Profit Margin | (12.01) | (11.41) | |
| Net Loss | (9.71) | (9.22) | |
| Gross Profit Margin | 1.15 | 1.10 |
Cogent Biosciences Growth Indicators
Investing in growth stocks can be very risky. If the company such as Cogent Biosciences does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 79.7 M |
Cogent Biosciences Current Valuation Indicators
Cogent Biosciences' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Cogent Biosciences' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Cogent Biosciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Cogent Biosciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Cogent Biosciences' worth.Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.